Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
24 févr. 2022 16h01 HE
|
Cyclerion Therapeutics, Inc.
Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment...
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
26 janv. 2022 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Lui Franciosi To Assess the Safety and Efficacy of a New Dementia Treatment
05 janv. 2022 16h00 HE
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be reviewing and monitoring the safety and efficacy of the new...
Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering
15 nov. 2021 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
09 nov. 2021 16h01 HE
|
Cyclerion Therapeutics, Inc.
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment...
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
22 sept. 2021 08h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function,...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
01 sept. 2021 19h45 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
23 août 2021 17h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
29 juil. 2021 17h00 HE
|
Cyclerion Therapeutics, Inc.
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive...
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
16 juin 2021 09h00 HE
|
Headlands Research
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- Headlands Research (www.headlandsresearch.com), a global next-generation clinical research site organization, is pleased to have supported Biogen...